Enoxaparin Sodium

Summary

Enoxaparin Sodium (CHEMBL1201476) is an approved oligosaccharide (ATC B01AB05) targeting SERPINC1; indicated across 34 conditions including venous thromboembolism and thrombotic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligosaccharide
• ATC class: B01AB05
• Targets: 1 (SERPINC1)
• Indications: 34 conditions
• Clinical trials: 276

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201476
Name	Enoxaparin Sodium
Type	Oligosaccharide
Max phase	4
ATC	B01AB05

Also known as: Clexane, Enoxaparin, Enoxaparin sodium, Enoxaparin sodium (preservative free), Enoxaparin sodium salt, Enoxaparina de sodio, Enoxaparine sodique, Inhixa, Klexane, Lovenox, Lovenox (preservative free), PK 10169

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SERPINC1	serpin family C member 1	Activation		0%	P01008

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SERPINC1.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	SERPINC1
R-HSA-140837	1	SERPINC1
R-HSA-140875	1	SERPINC1
R-HSA-140877	1	SERPINC1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	SERPINC1
Metabolism of proteins	1	SERPINC1
Post-translational protein modification	1	SERPINC1
Post-translational protein phosphorylation	1	SERPINC1
Fibrin formation	1	SERPINC1
Initiation of coagulation cascade	1	SERPINC1
Regulation of clotting cascade	1	SERPINC1
Amplification and propagation of coagulation cascade	1	SERPINC1

Dominant GO biological processes

GO term	Targets
blood coagulation	1
regulation of blood coagulation	1
hemostasis	1

Indications & clinical

Indications

34 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
venous thromboembolism	4	MONDO:0005399	EFO:0004286
thrombotic disease	4	MONDO:0000831	HP:0004419
myocardial infarction	4	MONDO:0005068	EFO:0000612
pulmonary embolism	4	MONDO:0005279	EFO:0003827
acute myocardial infarction	4	MONDO:0004781	EFO:0008583
obesity disorder	3	MONDO:0011122	EFO:0001073
neoplasm	3	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
fetal growth restriction	3	MONDO:0005030	EFO:0000495
habitual spontaneous abortion	3	MONDO:0006774	EFO:1000954
atrial fibrillation	3	MONDO:0004981	EFO:0000275
ST-elevation myocardial infarction	3	MONDO:0041656	EFO:0008585
myocardial ischemia	3	MONDO:0024644	EFO:1001375
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
intermediate coronary syndrome	3	MONDO:0006805	EFO:1000985
cirrhosis of liver	2	MONDO:0005155	EFO:0001422
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
stroke disorder	2	MONDO:0005098	EFO:0000712
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
carcinoma of esophagus	2	MONDO:0019086	EFO:0002916
staphylococcus aureus infection	2	MONDO:0005545	EFO:0005681
blood coagulation disease	2	MONDO:0001531	EFO:0009314
ovarian cancer	2	MONDO:0008170	MONDO:0008170
nephrotic syndrome	2	MONDO:0005377	EFO:0004255
acute coronary syndrome	1	MONDO:0005542	EFO:0005672
lymphoma	1	MONDO:0005062	EFO:0000574

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 276.

Phase distribution

Phase	Trials
PHASE3	79
PHASE4	65
PHASE2	55
Not specified	43
PHASE1	14
PHASE2/PHASE3	12
PHASE1/PHASE2	7
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03244020	PHASE4	ENROLLING_BY_INVITATION	LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
NCT04861103	PHASE4	RECRUITING	Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
NCT05245877	PHASE4	RECRUITING	Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05735639	PHASE4	RECRUITING	THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
NCT07132515	PHASE4	RECRUITING	Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
NCT07189897	PHASE4	RECRUITING	Apixaban or Enoxaparin After Head and Neck Cancer Surgery
NCT00077753	PHASE4	COMPLETED	EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
NCT00077805	PHASE4	COMPLETED	PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
NCT00077818	PHASE4	COMPLETED	Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
NCT00170378	PHASE4	COMPLETED	The Use of Low Molecular Weight Heparin in Traumatic Brain Injury
NCT00232271	PHASE4	TERMINATED	The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.
NCT00253396	PHASE4	COMPLETED	Patients Preference With Self-Injection: The PRISM Study
NCT00265993	PHASE4	COMPLETED	Enoxaparin in Acute Venous Thromboembolic Disease
NCT00289042	PHASE4	COMPLETED	Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
NCT00298285	PHASE4	COMPLETED	ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement
NCT00439855	PHASE4	COMPLETED	Enoxaparin Versus Unfractionated Heparin in PCI
NCT00444652	PHASE4	UNKNOWN	Thromboprophylaxis and Bariatric Surgery
NCT00518245	PHASE4	TERMINATED	Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)
NCT00585182	PHASE4	COMPLETED	Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
NCT00622648	PHASE4	COMPLETED	Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin
NCT00669149	PHASE4	TERMINATED	Anticoagulant Treatments and Percutaneous Coronary Angioplasty
NCT00699465	PHASE4	UNKNOWN	Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage
NCT00790387	PHASE4	COMPLETED	Tirofiban and Enoxaparin in High Risk Coronary Intervention
NCT00986076	PHASE4	COMPLETED	Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery
NCT01021488	PHASE4	UNKNOWN	Rosuvastatin for Preventing Deep Vein Thrombosis
NCT01063426	PHASE4	UNKNOWN	Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users
NCT01252420	PHASE4	UNKNOWN	Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis
NCT01354704	PHASE4	COMPLETED	Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin
NCT01729559	PHASE4	COMPLETED	Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
NCT01747746	PHASE4	COMPLETED	Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
NCT01798550	PHASE4	COMPLETED	Enoxaparin Dosing in Obesity
NCT01956955	PHASE4	UNKNOWN	Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism
NCT01970202	PHASE4	UNKNOWN	Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity
NCT01970280	PHASE4	UNKNOWN	Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients.
NCT02095509	PHASE4	COMPLETED	Pharmacokinetics of Enoxaparin in Intensive Care Patients
NCT02303171	PHASE4	UNKNOWN	Use of Warfarin After the First Trimester in Pregnant Women With APS
NCT02326051	PHASE4	COMPLETED	Timing of Initiation of LMWH Administration in Pregnant Women With APS
NCT02379663	PHASE4	COMPLETED	Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty
NCT02389582	PHASE4	COMPLETED	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
IDRAPARINUX	ChEMBL	Phase 3	SERPINC1
fondaparinux	PubChem	Approved	SERPINC1